Navigation Links
SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193

leverages its proprietary technologies through multiple strategic partners, including the National Institutes of Health and TransTech Pharma, Inc. For more information about SIGA, please visit SIGA's Web site at www.siga.com.

About the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a critical role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

The information contained in this press release does not necessarily reflect the position or policy of the U.S. government, and no official endorsement should be inferred.

Forward-looking Statements

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the safety or efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approval
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type Disasters; House Urged to Act on Strong Drug Safety Bill
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SIGA Passes First Hurdle with Lassa Fever Antiviral
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... AUSTIN, Texas, June 29, 2011 Ascension Orthopedics, Inc., the ... the PyroTITAN™ Humeral Resurfacing Implant in Geelong, Australia by Richard ... "The patient was a 57-year-old, active male with ... by a fall from a mountain bike and not improved ...
... 2011 Medicines can cure disease, relieve symptoms, and ... a lot of damage if taken incorrectly, when not ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Studies estimate that up ... be prevented. Learn how FDA—through its Safe ...
Cached Medicine Technology:Ascension Orthopedics Implants PyroTITAN™ in Geelong, Australia 2
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy ... its highest annual revenues in the past three years. Today, ... wedding dresses. , According to the sales manager of the ... for them in 2015. This point can be reflected on ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
(Date:1/22/2015)... Ga., USA (PRWEB) January 22, 2015 ... a statewide data management system with support from GEOSYSTEMS, ... , The new solution will leverage Hexagon Geospatial’s ... and vector data as well as point clouds and ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... , , SAN ... Cetyl Max/Flexadren mischaracterized certain facts associated with the ... Board: IAGX). Both companies extend their apologies to ... affected by the mischaracterization. , , ...
... , , MINNEAPOLIS, Aug. 13 ... will be the new Director of Research for the organization. Dr. ... of Oregon and the University of Minnesota. , , ... Minnesota and our research department," said David Willoughby, Chief Executive Officer ...
... activity reduces depression and fatigue , THURSDAY, Aug. 13 ... and depression experienced by leukemia patients who are undergoing ... people who did individualized exercise sessions while in the ... induction phase of leukemia treatment. The sessions included aerobic ...
... so high , , THURSDAY, Aug. 13 (HealthDay News) -- ... and policymakers would like, two U.S. health agencies have decided ... Centers for Disease Control and Prevention and the Office of ... and Human Services, are spending much of Thursday at CDC ...
... , SAN JOSE, Calif., Aug. 13 Human Pheromone Sciences, ... for the three and six months ended June 30, 2009. For the ... a 5% decrease from the revenues of $236,000 in the prior year ... as compared with a net loss of $88,000 ($0.02 per share) for ...
... ... health care plan currently under consideration in Congress. After pouring through the entire document, he ... is no coverage for illegal aliens, and the parental education is largely voluntary, and driven ... financial side. , ...
Cached Medicine News:Health News:Exercise May Help in Leukemia Recovery 2Health News:It's Time for More Moms to Breast-Feed, U.S. Officials Say 2Health News:It's Time for More Moms to Breast-Feed, U.S. Officials Say 3Health News:Human Pheromone Sciences Announces Second Quarter Results 2Health News:Human Pheromone Sciences Announces Second Quarter Results 3Health News:Human Pheromone Sciences Announces Second Quarter Results 4Health News:Analysis of the Proposed Health Care Legislation Finds Financial Aspects May be Difficult to Forecast 2
... the only four-color, automated benchtop flow cytometry ... cell sorting. Designed specifically to support a ... offers software instrument control, auto-sample loading, and ... productivity. FACSCalibur is fully modular so it ...
... mobile flow cytometer for any kind ... counting. The CyFlow SL analyzes forward ... with up to 3 fluorescence channels. ... is performed with a PC or ...
The Elecsys 2010 Rack System streamlines processes and allows for smooth implementation of laboratory automation....
... an automated, multiparametric immunoassay system. ... stores the calibration in the ... cost-per-patient result. Plus, with its ... of use and uni/bi-directional interface, ...
Medicine Products: